Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Arthritis Rheum ; 41(10): 1760-71, 1998 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-9778217

RESUMO

OBJECTIVE: To study the interaction of interleukin-1alpha (IL-1alpha) and oncostatin M (OSM) in promoting cartilage collagen destruction. METHODS: Bovine, porcine, and human cartilage and human chondrocytes were studied in culture. The levels of collagenase (matrix metalloproteinase 1 [MMP-1]) and tissue inhibitor of metalloproteinases 1 (TIMP-1) were measured by bioassay and enzyme-linked immunosorbent assay (ELISA). The levels of OSM in rheumatoid synovial fluid were measured by ELISA. RESULTS: When combined with OSM, IL-1alpha, IL-1beta, and tumor necrosis factor alpha released proteoglycan and collagen from cartilage. OSM was the only member of the IL-6 family to have this effect. Human tendon also responded to IL-1alpha and OSM. OSM increased the production of MMP-1 and TIMP-1 but when combined with IL-1alpha, synergistically promoted MMP-1 production in human chondrocytes and synovial fibroblasts. High levels of OSM were found in human rheumatoid synovial fluids, and confocal microscopy showed that OSM was produced by macrophages in rheumatoid synovial tissue. CONCLUSION: These results highlight an important new mechanism by which there is irreversible loss of collagen from cartilage.


Assuntos
Artrite Reumatoide/metabolismo , Colágeno/metabolismo , Tecido Conjuntivo/química , Inibidores do Crescimento/fisiologia , Peptídeos/fisiologia , Animais , Northern Blotting , Western Blotting , Cartilagem Articular/efeitos dos fármacos , Cartilagem Articular/enzimologia , Cartilagem Articular/metabolismo , Bovinos , Condrócitos/efeitos dos fármacos , Colagenases/metabolismo , Citocinas/metabolismo , Humanos , Interleucina-1/farmacologia , Interleucina-6/farmacologia , Articulação do Joelho/química , Microscopia Confocal , Oncostatina M , Osteoartrite/metabolismo , Fenótipo , Suínos , Líquido Sinovial/química , Membrana Sinovial/química , Membrana Sinovial/metabolismo , Tendões/efeitos dos fármacos
2.
Arthritis Rheum ; 44(7): 1620-32, 2001 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-11465713

RESUMO

OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects. METHODS: The release of collagen and proteoglycan was assessed in bovine and human cartilage explant cultures. Messenger RNA (mRNA) and protein production from immortalized human chondrocytes (T/C28a4) was analyzed by Northern blotting and specific enzyme-linked immunosorbent assays. Collagenase activity was measured by bioassay. Cell surface receptors were detected by flow cytometry. RESULTS: OSM in combination with IL-1alpha caused a rapid synergistic induction of matrix metalloproteinase 1 mRNA, which was sustained over a 72-hour period. Flow cytometric analyses detected both the OSM-specific receptor and the gp130 receptor at the chondrocyte cell surface, but failed to detect the leukemia inhibitory factor receptor (LIFR). Cartilage degradation assays revealed that, of the gp130 binding cytokines, only OSM and IL-6, in the presence of its soluble receptor (sIL-6R), were able to act synergistically with IL-1alpha to promote collagen release. CONCLUSION: This study demonstrates that IL-6 can mimic OSM in synergizing with IL-1alpha to induce chondrocyte-mediated cartilage collagen breakdown and collagenase production. In order to have this effect, IL-6 requires the presence of its soluble receptor. The apparent absence of LIFR explains why other gp130 binding cytokines do not act in synergy with IL-1alpha. Since OSM, IL-6, and sIL-6R levels have all been shown to be elevated in the rheumatoid joint, our findings suggest that these cytokines may be key mediators of cartilage collagen catabolism in the inflammatory arthritides.


Assuntos
Antígenos CD/metabolismo , Condrócitos/efeitos dos fármacos , Colágeno/metabolismo , Interleucina-1/farmacologia , Interleucina-6/farmacologia , Glicoproteínas de Membrana/metabolismo , Animais , Cartilagem Articular/citologia , Bovinos , Linhagem Celular Transformada , Condrócitos/citologia , Condrócitos/enzimologia , Fator Neurotrófico Ciliar/metabolismo , Fator Neurotrófico Ciliar/farmacologia , Receptor gp130 de Citocina , Citocinas/metabolismo , Citocinas/farmacologia , Sinergismo Farmacológico , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Inibidores do Crescimento/metabolismo , Inibidores do Crescimento/farmacologia , Humanos , Interleucina-1/metabolismo , Interleucina-11/metabolismo , Interleucina-11/farmacologia , Interleucina-6/metabolismo , Fator Inibidor de Leucemia , Linfocinas/metabolismo , Linfocinas/farmacologia , Metaloproteinase 1 da Matriz/genética , Metaloproteinase 1 da Matriz/metabolismo , Oncostatina M , Peptídeos/metabolismo , Peptídeos/farmacologia , RNA Mensageiro/análise , Receptores de Interleucina-6/metabolismo , Inibidor Tecidual de Metaloproteinase-1/genética , Inibidor Tecidual de Metaloproteinase-1/metabolismo , Inibidor Tecidual de Metaloproteinase-2/genética , Inibidor Tecidual de Metaloproteinase-2/metabolismo
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa